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was defined as achieving HbA1c below 7% without weight gain and with no 
hypoglycaemic events in 26 weeks. With the assumption that a payer would be 
interested in paying only for successfully treated patients, cost of control was 
subsequently defined as the price per patient achieving the composite endpoint. 
The relevant comparator drugs, glimepiride, rosiglitazone and insulin glargine, 
were defined as those found both in the ‘Liraglutide Effect and Action in 
Diabetes’ clinical trial programme and on the China national drug 
reimbursement list. The number needed to treat (NNT) for patients achieving the 
composite endpoint at week 26 was also investigated. Costs of drug, needle and 
self-monitoring blood glucose were accounted based on the marketed retail price 
published by National Development and Reform Commission in 2012 Chinese 
value. RESULTS: The NNT for patients on liraglutide 1.2mg was 3.1 for achieving 
the composite endpoint, compared to between 6.7 and 16.7 for the three 
comparator drugs. This lead to the cost per successfully treated patient to be 
between 17% and 68% higher with glimepiride, insulin glargine and rosiglitazone 
compared to liraglutide 1.2mg in China. CONCLUSIONS: By assessing the NNT to 
achieve HbA1c below 7% with no weight gain and no hypoglycaemic events and 
the cost per patient achieving this composite endpoint, liraglutide 1.2mg was a 
cost-saving approach for T2DM patients in comparison with glimepiride, insulin 
glargine and rosiglitazone in a Chinese setting.  
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OBJECTIVES: Compare health care resource use and costs in patients with type 2 
diabetes mellitus (T2DM) treated with saxagliptin or sitagliptin in the 6 months 
following treatment initiation. METHODS: Patients with T2DM treated with 
saxagliptin (N=13,929) or sitagliptin (N=36,813) in 2010 or later were identified in 
the Truven MarketScan database of commercially insured beneficiaries. Patients 
were required to have no claims of saxagliptin or sitagliptin in the 6 months 
prior to treatment initiation, ≥6 months of continuous eligibility before and after 
initiation (baseline and study period, respectively), and be 18 or older. 
Demographic characteristics and comorbidities were evaluated in the baseline 
period. All-cause and diabetes-related resource use and costs were evaluated 
during the study period. Chi-squared and Wilcoxon rank sum tests assessed 
differences in resources use rates and costs. GLM regression with a log link and 
gamma distribution estimated the treatment effect on study period costs, 
adjusting for baseline characteristics and costs. RESULTS: During the study 
period, compared with sitagliptin patients, saxagliptin patients experienced 
lower rates of all-cause hospitalization, emergency department visits, and other 
medical visits (7.2% vs. 10.6%, 14.1% vs. 17.5%, and 67.0% vs. 70.4%, respectively; 
p<0.001). All-cause medical and total costs were lower for saxagliptin patients 
than sitagliptin patients ($4,555 vs. 5,921; $7,346 vs. $8,797; all p<0.001). 
Substantial costs were attributable to hospitalizations, which were less costly for 
saxagliptin patients ($1,477 vs. $1,992; p<0.001). Diabetes-related medical and 
total costs were also significantly lower for saxagliptin patients ($1,084 vs. $1,454; 
$2,445 vs. $2,828; all p<0.001). After adjusting for baseline characteristics, 
significant differences in medical and total costs persisted (all-cause: $5,073 vs. 
$5,535; $7,802 vs. $8,302; diabetes related: $1,149 vs. $1,387; $2,510 vs. $2,772; all 
p<0.001). CONCLUSIONS: Patients initiating treatment with saxagliptin had 
lower resource use and costs in a 6-month follow-up period than patients 
initiating with sitagliptin.  
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OBJECTIVES: To compare annual costs between diabetic macular edema (DME), 
diabetic retinopathy (DR), and diabetes on the direct and indirect costs of US 
employees versus controls without diabetes. METHODS: Analysis of 2001-2012 
administrative claims from the HCMS Reference Database which contains 
anonymous data from >20 geographically-dispersed US employers (1.7 million+ 
employees) including manufacturing, insurance, retail, transportation, 
telecommunications. Employees with DME, DR and Diabetes were identified by 
ICD-9 codes. For DME/DR subjects, the index date was the date of the initial 
claim, and for the other cohorts, the average of DME/DR index dates. All subjects 
were required to have ≥12 months follow-up post index date. Cohorts were 
compared using two-part regression (logistic then generalized linear) models 
controlling for demographics and job-related information. Only subjects eligible 
for a benefit were included in the models for that benefit. All annual direct and 
indirect cost outcomes were inflation-adjusted to 2012 by the appropriate CPI 
index. RESULTS: The analysis identified 426,549 employees (DME=528; DR=1441; 
Diabetes=18,639; Controls=405,931). Medical costs for the cohorts were: 
DME=$12,125; DR=$13,547; Diabetes=$6,815; Controls=$3,326; Rx costs were: 
DME=$3,338; DR=$3,733; Diabetes=$2,502; Controls=$849. Medical and Rx costs 
were significantly different between all cohorts (P<0.0001) except DME-vs-DR. 
Indirect components: Sick Leave: DME=$1009; DR=$924; Diabetes=$830; 
Controls=$606; Short-term Disability: DME=$705; DR=$760; Diabetes=$483; 
Controls=$259; Long-term Disability: DME=$136; DR=$240; Diabetes=$66; 
Controls=$29; Workers’ Compensation: DME=$119; DR=$75; Diabetes=$229; 
Controls=$189. All DR-vs-Controls and Diabetes-vs-Controls comparisons were 
significant (P<0.03). Sick Leave and Short-term Disability for the other cohort 
pairs were also significant (P<0.05), except DME-vs-DR. Workers’ Compensation 
was significantly lower for DME-vs-Diabetes and DR-vs-Diabetes. CONCLUSIONS: 
This analysis shows the significant impact of DME and DR on employee direct 
and indirect costs across a variety of benefits. Overall employees with Diabetes 
were $5667 more expensive than Controls, and DME and DR resulted in 
incremental costs of $6507 and $8354 more than those with Diabetes, 
respectively.  
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OBJECTIVES: Strict control of glycemia in diabetic patients is impeded by the risk 
of hypoglycemia, especially when insulin is used. However, not all insulins have 
the same risk of hypoglycemia. The aim of this study was to study the cost of 
insulin related hypoglycemia requiring hospitalization (at least one overnight 
stay) in type-1 and 2 diabetes in Belgium. METHODS: A retrospective database 
study was conducted using the longitudinal IMS Hospital Disease Database (HDD 
2009), covering 34.3% of Belgian hospital beds. In this database hypoglycemic 
events can be identified based on ICD-9 codes (Diabetes hypoglycemic 
coma/insulin coma: 250.3; Diabetic hypoglycemia/hypoglycemic shock: 250.8; 
Anti-diabetic agent poisoning and adverse events: E932.3, 962.3). Number of stays 
for hypoglycemia, average length of stay (LOS) and on intensive care (ICU), in 
hospital mortality, re-hospitalizations for hypoglycemia and costs were 
estimated using SAS software. RESULTS: In the HDD 2291 patients were 
hospitalized for hypoglycemia due to insulin. In 2009, each patient had on 
average 1.12 hospitalizations. Eighty-five percent of those stays were in patients 
older than 55. The average LOS was 20.69 days (with 0.31 days on ICU) strongly 
driven by stays in the population >55 years (13 vs. 22 days; p<0.0001). Mortality 
during hospitalization was 6.78% driven by the age group older than 65 (3.49% vs. 
8.20%; p<0.0001). The average cost of a hospitalization was €11,066 [€10,077-
€11,359]. CONCLUSIONS: Hospitalizations for hypoglycemia due to insulin are 
expensive and result in an important in hospital mortality. Especially in the 
older age (>55), the costs for the health care payer are high due to extensive LOS. 
Interventions that can help reduce the risk of hypoglycemia, and as a 
consequence the burden on hospitals and society, without compromising 
glycemic control will help further improve diabetes management.  
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OBJECTIVES: To estimate the trend in direct and indirect costs among patients 
with diabetes in urban China from 2009 to 2011. METHODS: Data were obtained 
from the 2009-2011 Urban Resident Basic Medical Insurance (URBMI) household 
survey in 9 cities. Households were sampled to be representative of all 
households in these cities. Patients who self-reported to have a diabetes 
diagnosis were included. Annual costs per patient were estimated from the 
societal perspective, which included direct medical, direct non-medical and 
indirect costs. Direct medical costs included outpatient service, outpatient drug 
and inpatient costs. Outpatient service and drug costs were reported for the past 
2 weeks and extrapolated to 1 year. Inpatient costs were estimated based on the 
number of hospitalizations during the past year and costs for the most recent 
hospitalization. Direct non-medical costs included transportation, 
accommodation costs, etc. Indirect costs due to absenteeism were estimated for 
employed patients based on mean annual national wage of urban employees in 
China. All costs were inflated and converted to 2011 USD. RESULTS: A total of 
3,253 patients with self-reported diabetes diagnosis (N=1,078 in 2009, 1,114 in 
2010 and 1,061 in 2011) were included, with 49.1% female and a mean age of 64.0 
years. Mean annual direct medical costs were $1,303.2, $1,460.1 and $2,072.0 in 
2009, 2010 and 2011, respectively. Mean outpatient drug costs were $565.8, $683.7 
and $1034.5 in the three years, respectively, accounting for 43.4% to 49.9% of the 
direct medical costs. Insurance covered 42.8% to 45.5% of the direct medical 
costs. Mean annual direct non-medical costs were $111.9, $204.3 and $619.6 in 
2009, 2010 and 2011, respectively (P=0.224). The corresponding indirect costs 
were $135.0 (N=199), $201.3 (N=172) and $180.3 (N=167). CONCLUSIONS: Direct 
medical costs, outpatient drug costs and direct non-medical costs of diabetes 
increased numerically from 2009-2011 in urban China .  
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OBJECTIVES: To estimate medical expenditure for people with diabetes in Urban 
Employee Basic Medical Insurance (UEBMI) program in 2011 in Beijing, China. 
METHODS: Claims data from Beijing UEBMI database during 2010.10.01 to 
2011.09.30 was extracted with the criterion of people diagnosed with “diabetes 
mellitus” during this period. The Sum_All Medical method was used for 
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expenditure estimation. Information of physician visits, hospital admission rate, 
medical expenditure and its constitutions, length of stay were analyzed using 
STATA 11. RESULTS: A total of 612,227 insured urban employees were diabetes, 
accounting for 5.2% of population in the program of UEBMI in Beijing during 
2010.10.01 to 2011.09.30. Annual outpatient visits were37.4 times/person and the 
cost was CNY (Chinese Yuan) 388.42/visit, resulting in CNY 14526.91 for annual 
outpatient expenditure. The annual hospital admission rate of the investigated 
people with diabetes was 7.08%. For those who had used inpatient services, 
annual hospital admissions were 1.78 times/person (length of stay was 16.35 
days) and the cost was CNY 15070.99/admission, resulting in CNY 26826.37 for 
annual inpatient expenditure. The total of annual medical expenditure was 
CNY16426.21/person, of which, the cost of western drugs, Chinese traditional 
drugs, treatment, laboratory test, examination and others accounted for 48.46%, 
30.76%, 9.08%, 5.17%, 4.65% and 1.88% respectively. The cost of insulin accounts 
for 2.80% of total medical expenditure. CONCLUSIONS: The proportion of people 
with diabetes in the UEBMI program in Beijing is consistent with the high 
diabetes prevalence reported from other epidemiological studies. Diabetes is 
becoming a chronic epidemic disease with major public concern. This study 
showed that in Beijing, significant amount of societal and medical resources 
were consumed by people with diabetes. Early glycemic control and appropriate 
drug utilization should be the key to reduce the burden of diabetes.  
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OBJECTIVES: Cushing’s disease (CD) is a rare disorder resulting from 
adrenocorticotropic hormone secreting pituitary tumor; limited US data are 
available on health care utilization for this rare condition. We evaluated health 
care utilization and costs associated with CD. METHODS: We identified CD 
patients in 2010 in claims databases (Thomson Reuters MarketScan Commercial; 
IMS Health PharMetrics). Since no CD diagnosis code exists, patients were 
identified with a claim for Cushing’s syndrome and either benign pituitary 
adenomas or hypophysectomy (adenectomy) and continuous-enrollment in the 
study year. We estimated total and CD-related utilization and costs using 
pharmacy and medical claims. CD-related outcomes were determined using 
claims with primary diagnosis of Cushing’s syndrome, benign pituitary 
adenoma, or claims with CD treatment (pharmacologic/surgery/radiotherapy). 
RESULTS: We identified 685 CD patients across US (mean age: 41.7years; 81% 
female; mean Charlson-comorbidity: 1.6; mean no. chronic conditions: 4.2); 30.5% 
(209) patients had diabetes, 22.5% had psychiatric disturbances, 8.6% had 
osteoporosis, 8% had cardiovascular disease/stroke, 5.5% had kidney stones, and 
0.7% had compression fracture of vertebra. 38.4% patients had inpatient 
hospitalizations and 34.2% had emergency department visits. Patients had a 
mean of 19.8 physician office visits. CD-related hospitalization was observed in 
26.9%, emergency department visits in 0.9%, CD-treatment in 36.8%. Patients had 
mean of 3.2 CD-related visits. Mean overall costs were $34,992 (SD:$45,811; 
median:$18,031): $3,597 (SD:$6,323) were pharmacy and $31,395 (SD:$44,082) were 
medical costs. Of this total, CD-related costs accounted for $14,310 (SD:$25,161; 
median:$2,079): $9,353 (SD:$19,259) from treatment and $4,957 (SD:$11,805) from 
non-treatment costs. CONCLUSIONS: Economic burden of CD is substantial, with 
hospitalizations or emergency department visits observed in >34% patients, 19.8 
office visits/patient, and up to $35,000 in annual total cost. Direct CD-related 
costs are likely underestimated because of under-coding of CD in claims and use 
of primary diagnosis claims only. Future research should further examine CD-
comorbidity costs and impact of long-term comorbidities of CD.  
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OBJECTIVES: To assess a) the economic impact of diabetes on quality of life, 
disabilities and health utilities, the income, employment and education of patients 
and their families in Argentina, and b) compare these costs with those recorded in 
people without diabetes. METHODS: Case-control study comparing cases with 
T2DM with or without chronic complications and controls without diabetes (paired 
by age and gender) and social contexts. Data was obtained by telephone interviews 
(March-April 2011) using identical questionnaire. Interview data were 
supplemented with data obtained from clinical records to fully describe the 
subjects’ resources utilization and costs of care. Statistical analysis was done using 
ANOVA or Kruskal-Wallis and Chi-square (in proportions) tests and the SPSS 
version 15. The study had ethical clearance and all subjects provided oral informed 
consent. RESULTS: We interviewed 774 non diabetic controls, 387 people with 
T2DM without complications, and 387 people with T2DM and complications); 
mostly female (54.8% in each group). The diabetes duration in the group with 
complications was significantly higher than in the group without complications 
(8.1±8.4 vs. 10.8±9.0). Persons with T2DM with complications have significantly 
lower salaries, higher monthly expenditures (with lower expenditure/income ratio), 
lower percentage of people with university degree, higher hospitalization rate and 
resources consumption; they also have lost more working days (16.2) than those 
either with T2DM without complications (8.48) or those without T2DM (7.78). People 
with T2DM with complications have significantly higher direct medical and indirect 
cost. CONCLUSIONS: This report shows objectively the heavy burden of diabetes 
and its complications for the patient, its family, the health systems and the overall 
society in Argentina. The data provide a serious warning to health care authorities 
to strengthen the implementation of prevention strategies to reduce this burden.  
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OBJECTIVES: Type-2 diabetes mellitus (T2DM), the most common form of 
diabetes (>90% of all cases), is typically associated with adult obesity. Recently, 
increasing attention been given to the growing prevalence of disease among 
pediatric populations. This study assessed trends in pediatric T2DM 
hospitalization and aspects of related care in the US. METHODS: Data for 
pediatric (≤20 years) hospitalizations with a primary diagnosis of T2DM (ICD-9-
CM codes 250.x0 and 250.x2) from the 2000, 2003, 2006, and 2009 HCUP Kids’ 
Inpatient Databases were analyzed. Weighted estimates of the number of T2DM-
related hospitalizations and associated resource-based outcomes (i.e., total 
charges, length of stay [LOS]) were derived. RESULTS: Between 2000 and 2009, 
rates of pediatric T2DM-related hospitalizations (per 100,000 2010 US pediatric 
population) increased from 2.0/100,000 in 2000 to 2.7/100,000 in 2003 and 
3.5/100,000 in 2006, before falling modestly to 2.7/100,000 in 2009. Mean LOS for 
these hospitalizations remained fairly consistent over time (3.2 days in 2000, 3.3 
days in 2003, 3.1 days in 2006, and 2.9 days in 2009). Mean charges (2012 USD) for 
T2DM-related stays have increased nearly 34%, from $13,775 (2000) to $18,432 
(2009). Finally, total pediatric T2DM-related inpatient charges increased by more 
than 147% percent between 2000 and 2006, from $21.5M (2012 USD) to $53.3M, 
before falling slightly in 2009 to $42.4M. CONCLUSIONS: We observed increases 
in rates of pediatric T2DM-related hospitalization over time, with substantial 
growth in the economic burden associated with these stays (i.e., nearly a 150% 
increase in total charges between 2000 and 2006). The increasing hospitalization 
rates are consistent with growing prevalence of obesity among pediatrics in the 
US. These findings should further emphasize the need for interventions targeted 
at mitigating and managing factors associated with the risk of T2DM (e.g., 
obesity) among children.  
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OBJECTIVES: Patients with type 2 diabetes mellitus (T2DM) are at greater risk of 
experiencing a stroke or myocardial infarction (MI) than those without T2DM. A 
systematic literature review summarized published cost estimates of stroke and 
MI to better understand the economic burden for T2DM patients experiencing 
these comorbidities. METHODS: Electronic databases (2001-2011) and conference 
abstracts (2011-2012) were searched for publications on costs, utilities, and 
quality of life in the English language. This review reports the cost estimates 
identified. Costs were converted to year 2011 pounds sterling using purchasing 
power parity data and inflation indices. RESULTS: Fifty-one studies (11 primary 
cost studies; 40 economic evaluations) were identified presenting costs 
associated with an MI and/or stroke in patients with T2DM. All studies were 
performed in adults. No studies accounted for event severity. Nine primary cost 
studies reported per-patient direct costs for the year of a nonfatal event. Cost 
estimates ranged from £5,034 to £29,034 for MI and from £1,721 to £38,448 for 
stroke. For subsequent years, cost studies reported either annual or total follow-
up costs. Annual costs for stroke ranged from £639 to £12,831; for MI, 1 study 
reported a cost of £1,605. Total follow-up costs ranged from £284 to £8,988 for 
stroke and from £284 to £1,123 for MI. Only 1 study estimated direct costs for 
fatal events: £2,463 for MI and £6,645 for stroke. None of the 11 primary cost 
studies reported indirect costs associated with MI or stroke. However, 1 of the 40 
economic evaluations identified reported indirect costs for the event year and 
subsequent years. CONCLUSIONS: Literature on costs for MI and stroke specific 
to T2DM patients is sparse, with extensive variability between estimates 
identified. Further studies are needed to provide reliable cost estimates by 
severity of stroke and MI events in T2DM patients of all ages.  
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OBJECTIVES: To evaluate the short-term cost-effectiveness of Liraglutide versus 
Insulin Glargine in patients with type 2 diabetes (T2DM) using a composite 
endpoint from clinical trials and the incremental medical cost in a Chinese 
setting. METHODS: The cost-effectiveness analysis was calculated as the 
incremental cost per successfully treated patient of Liraglutide versus Insulin 
Glargine at week 26. Three cohorts of 100 patients each with Liraglutide 1.2mg, 
Liraglutide 1.8mg and Insulin Glargine were established for comparison. 
Effectiveness data of patients with T2DM achieving the composite endpoint of 
HbA1c<7.0%, no weight gain, and no hypoglycaemia at week 26 from a meta-
analysis. Safety data including hypoglycaemia and serious adverse events were 
derived from ‘Liraglutide Effect and Action in Diabetes’ trials. Medical costs 
